Vertex Pharma (VRTX) Tops Q3 EPS by 39c; Raises Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $548.80 -0.04%
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
KELYA, ROX, KEEL, More
Financial Fact:
Net loss attributable to Vertex: -38.84M
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.01, $0.39 better than the analyst estimate of $3.62. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.22 billion.
GUIDANCE:
Vertex Pharma sees FY2022 revenue of $8.8-8.9 billion, versus the prior of $8.6-$8.8 billion and the consensus of $8.77 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VRTX) PT Raised to $640 at UBS
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- MACOM Technology Solutions (MTSI) Tops Q4 EPS by 9c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
